Glycovirology is a novel glycan-based platform technology. The concept behind it is that carbohydrate drugs can be used as entry inhibitors that attach directly to the binding domain of different viruses. Our main drug candidate is designed to target the virus instead of the cell like most of the other compounds in development. There is also evidence that carbohydrate drugs are capable of modulating the immune system.
Bioxytran is developing an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Our initial targeted medical conditions are brain stroke, wound healing, and trauma. Most of these disease indications can use hyperbaric treatment, but it is costly and limited. In these indications hyperbaric treatment shows promise, but the duration of treatment is limited due to oxygen toxicity our oxygen transport molecule has the ability to impact the duration of treatment due to its drug design.
Bioxytran is developing two platform technologies in the fields of Glycovirology and Hypoxia and Degenerative Diseases. Learn more about our ProLectin & BXT pipelines here.
Bioxytran Inc. (OTCMKTS: BIXT) has a development stage hypoxia drug that that was initially targeting Acute Respiratory Distress Syndrome (ARDS) and stroke. Today they announced the licensing of a potentially phase 2 ready viral inhibitor which is designed to bind to a receptor on the protein spike of the virus.
Bioxytran Inc., a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a nanoscale oxygen carrier to affected tissues in the lungs, brain, heart, and other vital organs offers a new and possibly life-saving treatment option for late-stage 2019-nCoV.
The Nobel Prize in Physiology or Medicine for 2019 is awarded to William Kaelin, Jr., Sir Peter Ratcliffe, and Gregg Semenza. The need for oxygen to sustain life has been understood since the onset of modern biology; but the molecular mechanisms underlying how cells adapt to variations in oxygen supply were unknown until the prize-winning work described here. Animal cells undergo fundamental shifts in gene expression when there are changes in the oxygen levels around them.